Until the arrival of Plandai Biotechnology, Inc. (OTCQB – PLPL), even many wellness pundits were unaware that substantial increases in bioavailability and effectiveness of some products, like green tea extracts, were possible and would change the face of the industry.
On May 17, 2013, Goldman Small Cap Research published an Article on Plandai Biotechnology Inc. (OTCQB – PLPL). For your convenience, a copy of the article can be found below.
Health Benefits Down to a “T”
Health-conscious consumers seek out nutrients from a variety of products in order to reduce cholesterol and hypertension, lose weight, and promote wellness. Consumers derive these healthy nutrients by purchasing nutraceuticals and other items from companies that produce a whole host of products that cater to those consumers engaged in healthy lifestyles. Unfortunately, until the arrival of Plandai Biotechnology, Inc. (OTCQB – PLPL), even many wellness pundits were unaware that substantial increases in bioavailability and effectiveness of some products, like green tea extracts, were possible and would change the face of the industry.
For example, green tea, or green tea extracts are some of the most popular products in this segment. Its gallate catechins are known to have been used extremely effectively and efficiently as an antioxidant, weight loss aid by increasing metabolism, cold prevention, oral health, and cardiovascular health.
However, according to published USDA studies, the Plandai-grown product has demonstrated to have improved bioavailability over other products by 60-80%, far exceeding anything currently available today. To put those figures in perspective, in order to obtain the same bioavailability from competing products currently in the market, consumers would have to purchase and consume anywhere from 6-8 times as much product to generate an equivalent efficacy. With that in mind, why would a producer of products offering green tea extract in its stable of procure the extracts from anywhere else?
Plandai (OTCQB – PLPL) is able to succeed where the rest of the market has failed by controlling every aspect of the process from growing and providing the live tea leaves on its farms in South Africa, to producing the extracts in-house. Thus, Plandaí (OTCQB – PLPL) is able to guarantee continuity of supply as well as quality throughout the whole process.
Although the Company’s products will not be commercially available until later this year, Plandai (OTCQB – PLPL) just announced that it has signed separate development and distribution agreements in order to make its (green tea) Catechin Extract product widely available via nutraceutical products, in late 2013. Once these products become available, it should have a tremendous impact on Plandai (OTCQB – PLPL) and the entire nutrition market. After all, it is likely that consumers will seek out products promoting Phytofare™ extracts, given their substantially higher bioavailability.
GSCR was paid by a third party for this article. Compensation was in cash.